Data Insights

Valemetostat by Daiichi Sankyo for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Valemetostat by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Non-Small Cell Lung Cancer

Data Insights

Valemetostat by Daiichi Sankyo for Gastric Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Gastric Cancer

Data Insights

Valemetostat by Daiichi Sankyo for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Valemetostat by Daiichi Sankyo for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Diffuse Large B-Cell Lymphoma

Data Insights

Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Valemetostat by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Small-Cell Lung Cancer